Home › Targets › FGFR3

FGFR3 (2 companies · 6 programs)

Companies with an active program directed at FGFR3.

Tyra Biosciences, Inc. TYRA

dabogratinib — Low-Grade Upper Tract Urothelial Carcinoma Phase 2
dabogratinib — Non-Muscle Invasive Bladder Cancer Phase 2
dabogratinib — Achondroplasia Phase 2
TYRA-430 — Hepatocellular Carcinoma Phase 1
TYRA-200 — Intrahepatic Cholangiocarcinoma Phase 1

Cogent Biosciences, Inc. COGT

CGT4859 — Cholangiocarcinoma Phase 1